BR112022007677A2 - L-asparaginase recombinante - Google Patents

L-asparaginase recombinante

Info

Publication number
BR112022007677A2
BR112022007677A2 BR112022007677A BR112022007677A BR112022007677A2 BR 112022007677 A2 BR112022007677 A2 BR 112022007677A2 BR 112022007677 A BR112022007677 A BR 112022007677A BR 112022007677 A BR112022007677 A BR 112022007677A BR 112022007677 A2 BR112022007677 A2 BR 112022007677A2
Authority
BR
Brazil
Prior art keywords
asparaginase
recombinant
human subject
administering
treating
Prior art date
Application number
BR112022007677A
Other languages
English (en)
Inventor
Rim Choi Mi
Lin Tong
Silverman Jeffrey
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of BR112022007677A2 publication Critical patent/BR112022007677A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L-ASPARAGINASE RECOMBINANTE. A presente invenção provê composições e métodos para tratar uma doença tratável por depleção de asparagina em um sujeito humano compreendendo administrar a um sujeito humano uma L-asparaginase recombinante.
BR112022007677A 2019-10-25 2020-10-23 L-asparaginase recombinante BR112022007677A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926201P 2019-10-25 2019-10-25
US202063047222P 2020-07-01 2020-07-01
PCT/EP2020/079972 WO2021078988A1 (en) 2019-10-25 2020-10-23 Recombinant l-asparaginase

Publications (1)

Publication Number Publication Date
BR112022007677A2 true BR112022007677A2 (pt) 2022-10-25

Family

ID=73172647

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007677A BR112022007677A2 (pt) 2019-10-25 2020-10-23 L-asparaginase recombinante

Country Status (7)

Country Link
EP (1) EP4048303A1 (pt)
JP (1) JP2022553399A (pt)
AU (1) AU2020371963A1 (pt)
BR (1) BR112022007677A2 (pt)
CA (1) CA3156066A1 (pt)
TW (1) TW202134258A (pt)
WO (1) WO2021078988A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
WO2022217231A1 (en) * 2021-04-06 2022-10-13 Jazz Pharmaceuticals Ireland Ltd. Formulations of l-asparaginase
WO2022211829A1 (en) * 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2024015529A2 (en) 2022-07-14 2024-01-18 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003633A1 (en) * 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
AU2018354067B2 (en) * 2017-10-27 2023-03-30 Pfenex Inc. Method for production of recombinant Erwinia asparaginase
KR20200119234A (ko) * 2017-11-30 2020-10-19 재즈 파마슈티칼즈 아일랜드 리미티드 아스파라기나제를 이용한 치료 방법

Also Published As

Publication number Publication date
AU2020371963A1 (en) 2022-05-26
WO2021078988A1 (en) 2021-04-29
US20210308237A1 (en) 2021-10-07
EP4048303A1 (en) 2022-08-31
CA3156066A1 (en) 2021-04-29
JP2022553399A (ja) 2022-12-22
TW202134258A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
BR112022007677A2 (pt) L-asparaginase recombinante
CO2018003168A2 (es) Moduladores de la expresión de kras
CO2017007619A2 (es) Anticuerpos humanos contra glicoproteína del virus ébola
BR112017017286A2 (pt) protease de cisteína
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112017017284A2 (pt) protease de cisteína
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112012011331A2 (pt) uso de receptor similar à toll agonista para tratamento de câncer
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
AR101740A1 (es) Terapia de combinación y composiciones
BR112021018687A2 (pt) Combinação de dose fixa de canabinoides e cogumelos medicinais para prevenção e tratamento de câncer, doenças inflamatórias ou inflamatórias imunomediadas
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
EA202092748A1 (ru) Модуляторы экспрессии apol1
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
BR112018010705A2 (pt) vacinação com o domínio mica/b alfa 3 para o tratamento de câncer
BR112014006473A2 (pt) composição e método para tratamento de uma doença autoimune